Cost-effectiveness of lenacapavir for PrEP in Africa

By sjmartinez • September 24, 2024

Davey DJ, Jamieson L. Cost-effectiveness of lenacapavir for PrEP in Africa. Lancet HIV. 2024 Sep 20:S2352-3018(24)00242-X. doi: 10.1016/S2352-3018(24)00242-X. Epub ahead of print. PMID: 39312934.

Tags: Infectious Diseases, Publications

Prevalence of chlamydial, gonococcal and syphilis positivity by anatomical site and sex via self-collected biospecimens using at-home testing kits among a large and diverse cohort of men and women enrolled in the MACS/WIHS Combined Cohort Study (MWCCS) in the USA

Mimiaga MJ, Tian J, Chiu I, Yonko EA, Noori G, Aziz N, Jamieson BD, Qian Y, Alcaide ML, Augenbraun M, Friedman MR, Kempf MC, Dionne-Odom[...]

Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort

Jayavelu ND, Qi J, Milliren CE, Ozonoff A, Liu S, Levy O, Baden LR, Melamed E, McComsey GA, Cairns CB, Schaenman J, Shaw AC, Hafler[...]

No evidence of pitavastatin effect on muscle area or density among people with HIV

Erlandson KM, Umbleja T, Ribaudo HJ, Lu MT, Taron J, Diggs MR, Douglas PS, Fitch KV, Fichtenbaum CJ, Zanni MV, Aberg JA, Rodriguez-Barradas MC, Breaux[...]